FDA Withdraws Studies Supporting Safety of COVID and Shingles Vaccines

The U.S. The agency acted in recent months, blocking publication after determining the authors' broad conclusions exceeded what the underlying data supported. This move aligns with ongoing changes under the current administration. FDA scientists and data contractors reviewed millions of patient records for these studies, which aimed to affirm vaccine safety.

The research found serious side effects to be uncommon, but officials halted their release to maintain scientific integrity. The spokesperson emphasized that the FDA ensures all associated work meets high standards.

In October, agency scientists were directed to pull back two COVID vaccine studies already accepted for publication in medical journals. Earlier, in February, top FDA officials declined to approve submission of study abstracts on Shingrix, the shingles vaccine, to a drug safety conference. The HHS spokesperson noted that the shingles study design fell outside the agency's purview.

“The studies were withdrawn because the authors drew broad conclusions that were not supported by the underlying data.”

These actions occur under Health and Human Services Secretary Robert F. Kennedy Jr., who has expressed skepticism toward vaccines. Federal health agencies have recently softened COVID shot recommendations and reduced research on vaccine development. Efforts also include attempts to revise the childhood immunization schedule.

The withdrawals represent part of a pattern where the Trump administration has challenged established vaccine policies. Multiple sources confirm the studies' findings on rare side effects, but the agency prioritized data limitations over publication.

No contradictions appear across reports on the reasons for withdrawal. The New York Times first reported details of the blocked studies, including the involvement of data firms in analyzing patient records. Forbes highlighted that the research supported vaccine safety by showing infrequent serious side effects.

CNBC provided confirmation from the HHS spokesperson on the rationale.

Under the current leadership, federal agencies have scaled back certain vaccine initiatives. This includes limiting access to shots for some patients and questioning their efficacy. The spokesperson defended the FDA's decisions as protective of scientific processes.

No immediate plans for resubmission or revision of the studies were mentioned in the reports. Observers note these changes build on prior administration priorities. The studies' withdrawal underscores tensions between data-driven conclusions and agency standards.

While sources agree on the rarity of side effects, the block prevents broader dissemination of the findings. This could influence public perceptions of vaccine safety amid ongoing debates. Federal health officials continue to monitor vaccine data, but these specific studies remain unpublished.

The HHS spokesperson reiterated the commitment to high standards without providing further details on potential future releases. Reports indicate no disputes over the raw data itself.

The blocked publications may affect ongoing vaccine research and recommendations. Agencies have already adjusted guidelines, potentially impacting access for certain groups. Sources do not report immediate health consequences from the withdrawals. Efforts to overhaul immunization schedules persist, with the administration focusing on perceived overreach in prior policies.

The FDA's actions ensure conclusions align closely with evidence, according to officials. This approach aims to rebuild trust in health agencies.